使用抗抑郁药物治疗慢性眼痛。

IF 1.9 3区 医学 Q2 OPHTHALMOLOGY
Cornea Pub Date : 2024-11-01 Epub Date: 2024-07-23 DOI:10.1097/ICO.0000000000003646
Lindsey B De Lott, Noreen Khan, Maria A Woodward, Daniel J Clauw, Anat Galor
{"title":"使用抗抑郁药物治疗慢性眼痛。","authors":"Lindsey B De Lott, Noreen Khan, Maria A Woodward, Daniel J Clauw, Anat Galor","doi":"10.1097/ICO.0000000000003646","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Chronic ocular pain (COP) is a leading cause of eye care visits in the US and has a substantial impact on quality of life and visual functioning. Although many conditions underlie COP, such as dry eye disease or post-herpetic neuralgia, some people experience pain without significant ocular signs on examination or known risk factors (eg, traumatic injury). Antidepressant medications that act primarily on the central nervous system, such as tricyclic antidepressants and serotonin and norepinephrine reuptake inhibitors, are often used to treat patients with COP, but a recent Cochrane review and network meta-analysis investigating 25 different antidepressants concluded that only two serotonin and norepinephrine reuptake inhibitors, have sufficient data to support their use in chronic pain. For all other medications, the evidence was of low certainty. We contend that while these medications are not a cure-all for chronic pain or COP, it is premature to conclude that these medications have no role in their treatment. We provide a rationale for continued use of antidepressant medications as part of a multimodal targeted treatment for patients with COP.</p>","PeriodicalId":10710,"journal":{"name":"Cornea","volume":"43 11","pages":"1335-1339"},"PeriodicalIF":1.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444518/pdf/","citationCount":"0","resultStr":"{\"title\":\"Antidepressant Medication Use for Treatment of Chronic Ocular Pain.\",\"authors\":\"Lindsey B De Lott, Noreen Khan, Maria A Woodward, Daniel J Clauw, Anat Galor\",\"doi\":\"10.1097/ICO.0000000000003646\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>Chronic ocular pain (COP) is a leading cause of eye care visits in the US and has a substantial impact on quality of life and visual functioning. Although many conditions underlie COP, such as dry eye disease or post-herpetic neuralgia, some people experience pain without significant ocular signs on examination or known risk factors (eg, traumatic injury). Antidepressant medications that act primarily on the central nervous system, such as tricyclic antidepressants and serotonin and norepinephrine reuptake inhibitors, are often used to treat patients with COP, but a recent Cochrane review and network meta-analysis investigating 25 different antidepressants concluded that only two serotonin and norepinephrine reuptake inhibitors, have sufficient data to support their use in chronic pain. For all other medications, the evidence was of low certainty. We contend that while these medications are not a cure-all for chronic pain or COP, it is premature to conclude that these medications have no role in their treatment. We provide a rationale for continued use of antidepressant medications as part of a multimodal targeted treatment for patients with COP.</p>\",\"PeriodicalId\":10710,\"journal\":{\"name\":\"Cornea\",\"volume\":\"43 11\",\"pages\":\"1335-1339\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444518/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cornea\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/ICO.0000000000003646\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cornea","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ICO.0000000000003646","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

摘要:在美国,慢性眼痛(COP)是眼科就诊的主要原因之一,对生活质量和视觉功能有很大影响。虽然许多疾病(如干眼症或带状疱疹后遗神经痛)都是导致慢性眼痛的原因,但有些人在检查时并没有明显的眼部症状,也没有已知的风险因素(如外伤)。主要作用于中枢神经系统的抗抑郁药物,如三环类抗抑郁药物、血清素和去甲肾上腺素再摄取抑制剂,经常被用于治疗慢性阻塞性肺病患者,但最近的一项科克伦综述和网络荟萃分析调查了 25 种不同的抗抑郁药物,得出结论认为,只有两种血清素和去甲肾上腺素再摄取抑制剂有足够的数据支持其用于慢性疼痛。至于所有其他药物,证据的确定性都很低。我们认为,虽然这些药物不是治疗慢性疼痛或慢性阻塞性肺病的万能药,但现在就断定这些药物在治疗中没有作用还为时过早。我们为继续使用抗抑郁药物作为慢性阻塞性肺病患者多模式针对性治疗的一部分提供了依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antidepressant Medication Use for Treatment of Chronic Ocular Pain.

Abstract: Chronic ocular pain (COP) is a leading cause of eye care visits in the US and has a substantial impact on quality of life and visual functioning. Although many conditions underlie COP, such as dry eye disease or post-herpetic neuralgia, some people experience pain without significant ocular signs on examination or known risk factors (eg, traumatic injury). Antidepressant medications that act primarily on the central nervous system, such as tricyclic antidepressants and serotonin and norepinephrine reuptake inhibitors, are often used to treat patients with COP, but a recent Cochrane review and network meta-analysis investigating 25 different antidepressants concluded that only two serotonin and norepinephrine reuptake inhibitors, have sufficient data to support their use in chronic pain. For all other medications, the evidence was of low certainty. We contend that while these medications are not a cure-all for chronic pain or COP, it is premature to conclude that these medications have no role in their treatment. We provide a rationale for continued use of antidepressant medications as part of a multimodal targeted treatment for patients with COP.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cornea
Cornea 医学-眼科学
CiteScore
5.20
自引率
10.70%
发文量
354
审稿时长
3-6 weeks
期刊介绍: For corneal specialists and for all general ophthalmologists with an interest in this exciting subspecialty, Cornea brings together the latest clinical and basic research on the cornea and the anterior segment of the eye. Each volume is peer-reviewed by Cornea''s board of world-renowned experts and fully indexed in archival format. Your subscription brings you the latest developments in your field and a growing library of valuable professional references. Sponsored by The Cornea Society which was founded as the Castroviejo Cornea Society in 1975.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信